NCT04571398 is a clinical trial of ApricityRx mobile application in Cancer, sponsored by Apricity Health, Inc.

Who is sponsoring NCT04571398?

NCT04571398 is sponsored by Apricity Health, Inc.

What drugs are being tested in NCT04571398?

Interventions in NCT04571398: ApricityRx mobile application.

Is NCT04571398 still recruiting?

NCT04571398 is currently status unknown. Last updated 1 October 2020.

Last reviewed 2020-10-01 · How we verify

NCT04571398

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy

Status unknown Last updated 1 October 2020

What this trial tests

trial testing ApricityRx mobile application in Cancer in 100 participants. Status unknown.

Timeline

19 November 2019

Primary endpoint
15 October 2022

15 October 2023

Quick facts

Lead sponsor	Apricity Health, Inc
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	19 November 2019
Primary completion	15 October 2022
Estimated completion	15 October 2023
Sites	1 location across United States

Drugs / interventions tested

ApricityRx mobile application

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

Apricity Health, Inc

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study of ApricityRx™ for Management of IR-AEs for patients on I-O therapy. Patients currently receiving immunotherapy will be asked to consent to participate in ApricityRx software platform mobile telephone application to report symptoms, view educational content in video form about IO and irAEs and communicate with site study team.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The path forward for T cell engagers in patients with prostate cancer.
Subudhi SK, Siddiqui BA, Zarrabi KK, Kelly WK, et al · · 2026 · PMID 41734994 · DOI 10.1136/jitc-2025-013905

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04571398 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Apricity Health, Inc
Last refreshed: 1 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04571398.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing